59237-49-9

Usage

Uses

Since the provided materials do not specify the uses of Methyl 6-Methoxy-5-nitronicotinate, it is not possible to list its applications in different industries or as an application type for a specific reason. However, given that it is a nicotinic acid derivative, it could potentially be useful in chemical research or various industrial applications. It is always advisable when dealing with less-known chemicals to use appropriate care and precaution measures. Further research would be required to determine its specific applications and uses.

Upstream product

• 59237-53-5 methyl 6-chloro-5-nitro-pyridine-3-carboxylate 
• 124-41-4 sodium methylate 
• 6635-31-0 6-hydroxy-5-nitronicotinic acid 

Downstream Products

• 166742-23-0 methyl 5-amino-6-(methylthio)nicotinate 
• 59237-50-2 methyl 5-amino-6-methoxy-nicotinate 
• 1211532-25-0 6-methoxy-5-nitronicotinaldehyde 

Relevant academic research and scientific papers

Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases

New pyridin-2(1h)-one derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

PYRIDIN-2 (1H) -ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES

Compoundshaving the chemical structure of formula (I) are disclosed; as well as process for theirpreparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

Compounds as PDE IV and TNF inhibitors

This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and/or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.